Enfortumab Vedotin-Ejfv

Drug Profile

Enfortumab vedotin is an antibody-drug conjugate anti-cancer therapy marketed as Padcev for advanced urothelial cancer settings. It is a nectin-4-directed antibody linked to a microtubule inhibitor payload (MMAE). The FDA first approved it in 2019.

Drug Class: Nectin-4-directed antibody-drug conjugate; microtubule inhibitor conjugate
Approval Status: FDA approved in December 2019, with additional U.S. approval updates in 2021; EU approval in April 2022
Mechanism of Action: Targets nectin-4 via monoclonal antibody and delivers vedotin (MMAE) microtubule-inhibitor payload

Brand Names

Padcev

Indications

\Locally advanced or metastatic urothelial cancer after prior PD-1/PD-L1 inhibitor and platinum-containing chemotherapy, including specified cisplatin-ineligible settings\

Related News

Biosimilar and biologic updates include approvals, review decisions and licensing deals

Apr 29, 2026

Recent biosimilar and biologic developments included Health Canada approval of denosumab biosimilars, FDA review actions, and new licensing and commercialisation agreements. Other updates covered court, trial and reimbursement agenda decisions.

Merck Presents Bladder and Kidney Cancer Data at 2026 ASCO GU Symposium

Mar 12, 2026

Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.

Key Trial Data Presented at 2026 ASCO Genitourinary Cancers Symposium

Mar 04, 2026

The 2026 ASCO GU Symposium featured significant trial results in renal cell carcinoma, urothelial carcinoma, and prostate cancer, including data from LITESPARK-022, KEYNOTE-B15, SunRISE-2, and PEACE-3 studies.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT04887870	Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study	COMPLETED	PHASE2/PHASE3